Ultragenyx Pharmaceutical Inc.
- RARE
- NASDAQ
- Biotechnology
- Rare Genetic Disease Therapeutics
$15.07
Today +3.65%Quote Oct 19, 2026, 08:00 PM UTC
+0.28%over the last month
Max drawdown −7.7%From 1-month high −6.9%3 months −49.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets.
Where the money comes from
Q2 2026 revenue $214.0M
- Product$112.0M52.3%
- Royalty$102.0M47.7%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1,371
Founded
2010
Market value
$1.49B
Quote Oct 19
Floor
$14.46
4.0% below price
Resistance
$15.10
0.2% above price
Price vs analyst targets
34 analysts
Lowest target
$16.00Highest target
$39.00
$16.00Highest target
$39.00
- Price $15.07
- Average target $25.46
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 69% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RAREPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free